{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:49:13Z","timestamp":1788216553456,"version":"build-2803163510"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1097\/ico.0b013e318180e50f","type":"journal-article","created":{"date-parts":[[2008,11,5]],"date-time":"2008-11-05T03:11:30Z","timestamp":1225854690000},"page":"1195-1199","source":"Crossref","is-referenced-by-count":51,"title":["Bevacizumab (Avastin) and Argon Laser to Treat Neovascularization in Corneal Transplant Surgery"],"prefix":"10.1097","volume":"27","author":[{"given":"Georg","family":"Gerten","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-23-20210204","first-page":"2034","article-title":"Corneal graft rejection: incidence, manifestation, and interaction of clinical subtypes.","volume":"24","author":"Pleyer","year":"1992","journal-title":"Transplant Proc"},{"key":"R2-23-20210204","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/archopht.121.8.1087","article-title":"Risk factors for various causes of failure in initial corneal grafts.","volume":"121","author":"Price","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"R3-23-20210204","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.ophtha.2006.12.012","article-title":"Corneal transplant survival after onset of severe endothelial rejection.","volume":"114","author":"Wagoner","year":"2007","journal-title":"Ophthalmology"},{"key":"R4-23-20210204","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00347-007-1512-2","article-title":"Inhibition of angiogenesis in the anterior chamber of the eye.","volume":"104","author":"Bock","year":"2007","journal-title":"Ophthalmologe"},{"key":"R5-23-20210204","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00417-002-0496-5","article-title":"Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study.","volume":"240","author":"Kuchle","year":"2002","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R6-23-20210204","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00417-006-0410-7","article-title":"Clear graft survival and immune reactions following emergency keratoplasty.","volume":"245","author":"Maier","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R7-23-20210204","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","article-title":"Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.","volume":"48","author":"Bock","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R8-23-20210204","first-page":"2127","article-title":"Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin.","volume":"43","author":"Cursiefen","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R9-23-20210204","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00347-006-1469-6","article-title":"Typing for HLA matching. Advantages for keratoplasty.","volume":"104","author":"Ignatius","year":"2007","journal-title":"Ophthalmologe"},{"key":"R10-23-20210204","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/00003226-200304000-00021","article-title":"Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology.","volume":"22","author":"Cursiefen","year":"2003","journal-title":"Cornea"},{"key":"R11-23-20210204","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s004170100285","article-title":"Systemic mycophenolate mofetil in comparison with systemic cyclosporine A in high-risk keratoplasty patients: 3 years results of a randomized prospective clinical trial.","volume":"239","author":"Reinhard","year":"2001","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R12-23-20210204","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s003470170077","article-title":"Toric intraocular lenses. Clinical results and rotational stability.","volume":"98","author":"Gerten","year":"2001","journal-title":"Ophthalmologe"},{"key":"R13-23-20210204","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0161-6420(03)00659-6","article-title":"Impact of graft diameter on corneal power and the regularity of postkeratoplasty astigmatism before and after suture removal.","volume":"110","author":"Seitz","year":"2003","journal-title":"Ophthalmology"},{"key":"R14-23-20210204","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/sj.eye.6700636","article-title":"Improvement of graft prognosis in penetrating normal-risk keratoplasty by HLA class I and II matching.","volume":"18","author":"Reinhard","year":"2004","journal-title":"Eye"},{"key":"R16-23-20210204","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00347-007-1516-y","article-title":"Topical immunosuppressives after penetrating keratoplasty.","volume":"104","author":"Birnbaum","year":"2007","journal-title":"Ophthalmologe"},{"key":"R17-23-20210204","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00347-007-1517-x","article-title":"Systemic immunosuppressives after penetrating keratoplasty.","volume":"104","author":"Reis","year":"2007","journal-title":"Ophthalmologe"},{"key":"R18-23-20210204","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1097\/00003226-200211000-00007","article-title":"Fluorescein-potentiated argon laser therapy improves symptoms and appearance of corneal neovascularization.","volume":"21","author":"Gordon","year":"2002","journal-title":"Cornea"},{"key":"R19-23-20210204","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00347-006-1400-1","article-title":"In vitro and in vivo investigations on the treatment of presbyopia using femtosecond lasers.","volume":"104","author":"Gerten","year":"2007","journal-title":"Ophthalmologe"},{"key":"R20-23-20210204","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/00055735-200108000-00002","article-title":"Corneal neovascularisation.","volume":"12","author":"Chang","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"key":"R21-23-20210204","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1055\/s-2005-858449","article-title":"Neovascularization of the cornea.","volume":"222","author":"Mazhdrakova","year":"2005","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"R22-23-20210204","first-page":"18","article-title":"Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization.","volume":"39","author":"Amano","year":"1998","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R23-23-20210204","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1755-3768.2007.00979.x","article-title":"Guidance for the treatment of neovascular age-related macular degeneration.","volume":"85","author":"Schmidt-Erfurth","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"key":"R24-23-20210204","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularization by bevacizumab (Avastin).","volume":"91","author":"Manzano","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R25-23-20210204","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/ICO.0b013e3180de1d0a","article-title":"Safety profile of bevacizumab on cultured human corneal cells.","volume":"26","author":"Yoeruek","year":"2007","journal-title":"Cornea"},{"key":"R26-23-20210204","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/j.jcrs.2007.07.012","article-title":"Subconjunctival bevacizumab for vascularized rejected corneal grafts.","volume":"33","author":"Awadein","year":"2007","journal-title":"J Cataract Refract Surg"},{"key":"R27-23-20210204","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.ophtha.2007.05.016","article-title":"Bevacizumab for graft rejection.","volume":"114","author":"Harooni","year":"2007","journal-title":"Ophthalmology"},{"key":"R28-23-20210204","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.TP.0000158022.62059.F2","article-title":"Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: a retrospective study.","volume":"79","author":"Birnbaum","year":"2005","journal-title":"Transplantation"},{"key":"R29-23-20210204","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s004170050330","article-title":"Effect of thalidomide and structurally related compounds on corneal angiogenesis is comparable to their teratological potency.","volume":"237","author":"Joussen","year":"1999","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R30-23-20210204","first-page":"65","article-title":"Four years experience with triple procedures in herpes-afflicted eyes.","volume":"2","author":"Sundmacher","year":"1993","journal-title":"Ger J Ophthalmol"},{"key":"R31-23-20210204","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors.","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"R32-23-20210204","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab therapy for corneal neovascularization.","volume":"125","author":"De Stafeno","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R33-23-20210204","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","article-title":"Subconjunctival bevacizumab for corneal neovascularization.","volume":"245","author":"Erdurmus","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R35-23-20210204","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3928\/1081-597X-20050101-11","article-title":"Hyperopic laser in situ keratomileusis with 5.5-, 6.5-, and 7.0-mm optical zones.","volume":"21","author":"Kermani","year":"2005","journal-title":"J Refract Surg"}],"container-title":["Cornea"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ICO.0b013e318180e50f","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:12:10Z","timestamp":1786036330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00003226-200812000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/ico.0b013e318180e50f","relation":{},"ISSN":["0277-3740"],"issn-type":[{"value":"0277-3740","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}